2022
DOI: 10.21608/asmj.2022.233502
|View full text |Cite
|
Sign up to set email alerts
|

Role of FDG Pet/Ct in Evaluation of Patients With Metastatic Cancer Breast

Abstract: Background: Many studies have pointed out the role of 18F-FDG PET/CT in the assessment of metastatic breast cancer patients, compared to conventional imaging. Using the FDG PET metabolic parameters to measure tumor burden shows potentiality to predict their survival.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles